Filing Analysis
TAO Synergies Inc. held its Annual Meeting of Stockholders on December 18, 2025, where shareholders approved several key proposals including the election of a new director and an amendment to the equity incentive plan. Notably, shareholders also approved the issuance of common stock underlying convertible preferred stock and warrants to comply with Nasdaq Listing Rule 5635(d).
🚩 Red Flags
- Significant potential dilution: Approval of issuance of common stock underlying convertible preferred stock/warrants that could exceed 20% of the company's Common Stock.
- High concentration of voting power: Quorum was only achieved with ~43.18% of outstanding shares, indicating a significant portion of the float is not participating in governance.
📋 Key Facts
- Annual Meeting held on December 18, 2025.
- Bruce T. Bernstein elected to the Board of Directors until 2028 (1,040,943 votes in favor).
- Shareholders approved an amendment to the 2020 Equity Incentive Plan, increasing reserved shares by 500,000 to a total of 3,175,000.
- Shareholders approved the issuance of common stock underlying convertible preferred stock and warrants (per Nasdaq Rule 5635(d)) in an amount potentially exceeding 20% of outstanding Common Stock.
- Ratification of Stephano Slack LLC as independent registered public accounting firm for FY2025 was approved.
- Quorum represented by 43.18% of outstanding shares (3,318,341 shares).
TAO Synergies Inc. entered into a $11.0 million private placement of Series E Convertible Preferred Stock and warrants to accredited investors. The deal includes highly dilutive terms, including a 7% cumulative dividend (increasing to 15% upon triggering events) and 'full ratchet' anti-dilution protection on warrants.
🚩 Red Flags
- Highly dilutive financing: Potential issuance of up to 2,750,000 new shares (1.375M via conversion + 1.375M via warrants).
- Full ratchet anti-dilution protection on warrants is extremely investor-friendly and highly dilutive for existing shareholders.
- Dividend step-up: Dividends increase from 7% to 15% upon 'Triggering Events' (e.g., failure to maintain registration statement).
- Redemption risk: Holders can require cash redemption of preferred stock upon triggering events.
- Nasdaq compliance requirement: Company must seek stockholder approval for issuances exceeding 19.99% by Dec 31, 2025.
📋 Key Facts
- Aggregate gross proceeds expected: $11.0 million.
- Issuance of 11,000 shares of Series E Convertible Preferred Stock at $1,000 per share.
- Initial conversion price of $8.00 per share into up to 1,375,000 common shares.
- Warrants issued for up to 1,375,000 shares of Common Stock at an exercise price of $8.00.
- Preferred stock carries a 7% annual dividend (compounded quarterly), which jumps to 15% upon 'Triggering Events'.
- Warrants include 'full ratchet' anti-dilution protection for any future issuances below $8.00.
- Placement agent (GP Nurmenkari Inc.) to receive 8.0% cash fee plus warrants equal to 4.0% of the conversion amount.
TAO Synergies Inc. announced the voluntary resignation of two board members, Jonathan Schechter and Dr. Alan Tuchman, while appointing Robert Ephron to the Board. Additionally, the company engaged Joseph Jacks as an advisor for a digital asset treasury strategy involving the issuance of warrants.
🚩 Red Flags
- Multiple board departures in a single filing (Schechter and Tuchman).
- Issuance of warrants to an advisor as part of a consulting agreement, which can be dilutive.
📋 Key Facts
- Jonathan Schechter resigned from the Board and all committees on August 28, 2025 (voluntary).
- Dr. Alan Tuchman resigned from the Board but will continue as Chief Medical Officer on August 28, 2025.
- Robert Ephron appointed to the Board on August 29, 2025; joins from JK Polk Holdings with experience at Paramount and Viacom.
- Mr. Ephron waived his initial option grant upon joining the Board.
- Engaged Joseph Jacks as an advisor for digital asset treasury strategy (announced Aug 26, 2025).
- Issued warrants to Joseph Jacks for 100,000 shares of common stock at $8.40 per share; 5-year expiration.
TAO Synergies Inc. held a Special Meeting of Stockholders on August 6, 2025, where shareholders approved the issuance of common stock underlying convertible preferred stock and warrants, as well as an amendment to the company's Equity Incentive Plan.
🚩 Red Flags
- Significant potential dilution: The approved issuance under Proposal 1 could exceed 20% of total outstanding shares, including anti-dilution adjustments.
- Heavy reliance on convertible instruments (convertible preferred stock and warrants) which often lead to downward pressure on share price upon conversion.
📋 Key Facts
- Stockholders approved Proposal 1: Issuance of Common Stock underlying shares of convertible preferred stock and warrants (to comply with Nasdaq Listing Rules 5635(c) and 5635(d)).
- The issuance amount is equal to or in excess of 20% of the Company’s Common Stock outstanding before the issuance.
- Stockholders approved Proposal 2: Amendment to the 2020 Equity Incentive Plan, increasing shares reserved for issuance by 2,000,000 shares (totaling 2,675,000 shares).
- Quorum was present with 35.23% of outstanding shares represented at the meeting.
- Proposal 1 received 500,450 votes in favor and 66,872 against.
TAO Synergies Inc. announced a digital asset treasury strategy involving the acquisition of TAO tokens. As of August 6, 2025, the company has purchased an aggregate total of 42,111 TAO tokens.
🚩 Red Flags
- High volatility risk associated with digital asset (crypto) treasury strategies in micro-cap companies.
📋 Key Facts
- Company is implementing a digital asset treasury strategy directed toward TAO.
- Aggregate purchases to date amount to 42,111 TAO tokens.
- The announcement was made via press release on August 6, 2025.
TAO Synergies Inc. announced a digital asset treasury strategy involving the acquisition of TAO tokens. As of July 17, 2025, the company has purchased a total of 29,899 TAO tokens for approximately $10 million.
🚩 Red Flags
- Increased exposure to highly volatile digital assets (TAO) within the corporate treasury.
📋 Key Facts
- Company acquired 29,899 TAO tokens as part of a digital asset treasury strategy.
- Total investment in TAO tokens to date is approximately $10 million.
- The acquisition was announced via press release on July 17, 2025.
The company is correcting a previous 8-K to clarify that Dr. Alan J. Tuchman, M.D. remains on the Board of Directors despite resigning as CEO. Additionally, the company has undergone a name change from Synaptogenix, Inc. to TAO Synergies Inc., with a ticker symbol change from SNPX to TAOX effective July 1, 2025.
🚩 Red Flags
- Significant reduction in CEO compensation (to $7,500/month) may indicate liquidity constraints or a shift in management structure to preserve cash.
- Correction of previous material error regarding officer departure status suggests administrative oversight in prior filings.
📋 Key Facts
- Dr. Alan J. Tuchman, M.D. resigned as CEO effective June 8, 2025, but remains on the Board and will serve as Chief Medical Officer.
- Dr. Tuchman's base monthly salary has been reduced to $7,500 per month following his resignation as CEO.
- The company changed its name from Synaptogenix, Inc. to TAO Synergies Inc., effective June 26, 2025.
- Ticker symbol change from 'SNPX' to 'TAOX' on Nasdaq Capital Market is expected to be effective July 1, 2025.
- The name change was approved by the Board of Directors without requiring stockholder approval.
Synaptogenix, Inc. announced the initial purchase of TAO cryptocurrency as part of a new treasury strategy and has engaged BitGo to provide custody, staking, and trading services for these assets.
🚩 Red Flags
- Increased volatility risk due to exposure to highly volatile digital assets (TAO).
- Shift in corporate focus from primary business operations toward cryptocurrency treasury management/yield generation.
📋 Key Facts
- Company initiated its first purchase of TAO cryptocurrency on June 24, 2025.
- BitGo Trust Company, Inc. selected for qualified custody, staking, and trading services.
- Assets will be held in regulated, insured cold storage via BitGo.
- The company has already begun generating revenue through TAO staking.
- Initial TAO acquisition was funded using existing cash reserves and the balance sheet.
Synaptogenix, Inc. entered into a $5.5 million private placement of Series D convertible preferred stock and warrants to fund general corporate purposes and a new cryptocurrency treasury strategy involving Bittensor (TAO). The deal includes highly dilutive terms, including a full-ratchet anti-dilution provision on warrants and mandatory cash redemptions starting September 2025.
🚩 Red Flags
- Highly dilutive structure: The potential conversion/exercise could result in over 1.8 million new shares, significantly increasing the float.
- Full-ratchet anti-dilution on warrants: This is a highly aggressive term that protects investors at the expense of existing shareholders during future down-rounds.
- Mandatory cash redemptions: The company must pay back the preferred stock in cash starting Q3 2025, creating significant liquidity pressure.
- High dividend rate: Preferred stock carries a 5% cash dividend, which jumps to 15% per annum upon 'Triggering Events'.
- Registration Rights Agreement (RRA) penalties: The company faces liquidated damages if it fails to make the registration statement effective promptly.
📋 Key Facts
- Private placement of $5.5 million in Series D convertible preferred stock to accredited investors.
- Preferred stock is convertible into up to 1,833,333 shares of common stock at an initial price of $3.00 per share.
- Issuance includes warrants to purchase up to 1,833,333 shares of common stock at $3.00 per share.
- The company intends to use proceeds to acquire $10 million of Bittensor (TAO) tokens as a treasury reserve asset.
- Preferred stock requires cash redemption in equal quarterly installments starting September 30, 2025, at 107% of the installment amount.
- Warrants include a 'full ratchet' anti-dilution adjustment if common stock is issued below $3.00.
Synaptogenix, Inc. has implemented aggressive cost-cutting measures, including significant salary reductions for the CEO and CSO, alongside the termination of a Phase 1 clinical trial due to slow enrollment. The company is also forming a special committee to explore strategic opportunities, signaling potential distress or restructuring.
🚩 Red Flags
- Significant reduction in executive compensation (CEO and CSO) typically indicates severe liquidity constraints or cash runway issues.
- Termination of clinical trials for the lead drug candidate (Bryostatin-1) due to enrollment failures, impacting the core value proposition.
- Formation of a 'special committee' often precedes M&A activity, spin-offs, or significant corporate restructuring in distressed micro-caps.
📋 Key Facts
- CEO Dr. Alan J. Tuchman's term extended through Jan 31, 2025, with automatic monthly renewals; base salary reduced to $12,500/month effective Jan 1, 2025.
- CSO Dr. Daniel L. Alkon entering a new consulting agreement effective Jan 1, 2025, with fee reduced to $16,000/month.
- Termination of Phase 1 clinical trial for Bryostatin-1 in multiple sclerosis due to slow enrollment rates.
- Formation of a special committee to explore strategic opportunities to enhance investor value.
Synaptogenix, Inc. held its Annual Meeting of Stockholders on December 6, 2024, reporting results for four proposals including director elections and equity plan amendments.
🚩 Red Flags
- Proposal 2 involves authorization of share issuance that could lead to significant dilution (up to 20% of common stock outstanding) via convertible preferred stock and warrants.
📋 Key Facts
- Quorum was present with 846,988 shares (approx. 54.03% of outstanding common stock) represented in person or by proxy.
- Joshua Silverman and William S. Singer were elected to the Board of Directors until the 2027 annual meeting.
- Stockholders approved a proposal authorizing the Board to issue common stock underlying convertible preferred stock/warrants from a Sept 10, 2024 agreement (up to 20% of outstanding shares).
- The 2020 Equity Incentive Plan was amended to increase authorized shares from 175,000 to 675,000.
- Stockholders ratified Stephano Slack as the independent registered public accounting firm for fiscal year 2024.
Synaptogenix, Inc. announced the resignation of its independent auditor, Morison Cogen LLP, effective September 30, 2024, due to the firm's decision to exit providing audit services to publicly traded companies. The company has appointed Stephano Slack LLC as its new independent registered public accounting firm for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Auditor change: While the reason provided (firm exiting public company audits) is a structural business decision by the auditor rather than a dispute with management, auditor changes in micro-cap companies often trigger increased scrutiny and potential delays in financial reporting.
📋 Key Facts
- Morison Cogen LLP resigned on September 30, 2024.
- Resignation reason: Morison Cogen is exiting from providing audit services to publicly traded companies.
- The company stated there were no disagreements with the outgoing auditor regarding accounting principles or practices for fiscal years 2022, 2023, and interim 2024.
- Stephano Slack LLC was engaged as the new auditor on October 4, 2024.
- The change is effective for the fiscal year ending December 31, 2024.
Synaptogenix, Inc. has completed a $5 million private placement of newly created Series C Convertible Preferred Stock and warrants. The terms include mandatory cash redemptions starting October 31, 2024, and significant dividend escalations in the event of default.
🚩 Red Flags
- Mandatory cash redemptions starting in less than two months (Oct 31, 2024) create immediate liquidity pressure.
- Dividend step-up to 15% upon 'Triggering Events' (e.g., failure to pay or failure to maintain registration statement).
- Restrictive covenants regarding indebtedness, asset transfers, and cash distributions.
- Potential for significant dilution via the Series C conversion feature.
📋 Key Facts
- Completed private placement of Series C Convertible Preferred Stock and warrants for $5 million gross proceeds.
- Initial conversion price set at $4.00 per share.
- Mandatory cash redemption in equal quarterly installments commencing October 31, 2024, at 107% of the installment amount.
- Preferred shares carry a 5% annual dividend, which increases to 15% per annum upon a 'Triggering Event'.
- The company must seek stockholder approval for issuances exceeding 19.99% of outstanding shares by December 31, 2024.
- Redemption rights can be exercised by holders one year after issuance.
Synaptogenix, Inc. entered into a $5.0 million securities offering involving Series C convertible preferred stock and warrants via both a registered direct offering and a private placement. The deal includes highly dilutive terms, including a 'full ratchet' anti-dilution provision on warrants and significant redemption obligations.
🚩 Red Flags
- Highly dilutive structure: Potential for up to 1,250,000 warrant shares plus over 1.2 million conversion shares.
- Full Ratchet Anti-Dilution: Warrants are subject to full ratchet adjustments, which is extremely punitive to existing shareholders in down rounds.
- Redemption Obligations: Mandatory quarterly cash redemptions starting Oct 31, 2024, create significant liquidity pressure.
- Death Spiral Features: The combination of high dividends (up to 15%) and redemption rights upon 'Triggering Events' (like failure to maintain registration) is characteristic of predatory financing.
- Registration Rights Agreement: Includes liquidated damages if the company fails to register shares promptly.
📋 Key Facts
- Aggregate gross proceeds from the Offering are expected to be $5.0 million.
- The offering consists of 1,793 shares of Series C Preferred Stock (Registered) and 3,207 shares of Unregistered Preferred Shares.
- Conversion price for Preferred Stock is set at an initial $4.00 per share.
- Warrants were issued to acquire up to 1,250,000 shares of Common Stock with a five-year term and $4.00 exercise price.
- The Company must redeem Series C Preferred Shares in quarterly installments starting October 31, 2024, at 107% of the installment amount.
- Preferred shares carry a 5% cash dividend, which increases to 15% per annum upon a 'Triggering Event'.
- Warrants include a 'full ratchet' anti-dilution adjustment if common stock is issued below $4.00.
Synaptogenix, Inc. filed an amendment to its Certificate of Designations to extend the maturity date of its Series B Convertible Preferred Stock from August 31, 2024, to September 9, 2024.
🚩 Red Flags
- Extremely short-term maturity extension (9 days) suggests imminent liquidity pressure or a struggle to secure long-term financing.
- The need for rapid, incremental extensions often precedes a default or restructuring event.
📋 Key Facts
- The Company extended the maturity date of Series B Convertible Preferred Stock by only 9 days (from Aug 31 to Sept 9, 2024).
- The extension is subject to further extensions pursuant to the terms of the Certificate of Designations.
- Amendment filed with the Delaware Secretary of State on September 3, 2024.
Synaptogenix, Inc. entered into a third amendment to the employment offer letter for its CEO, Alan J. Tuchman, Ph.D., effective June 7, 2024. The amendment extends his term through December 7, 2024, with provisions for automatic monthly renewals.
🚩 Red Flags
- Short-term extension (only through Dec 2024) may suggest uncertainty regarding long-term leadership stability or upcoming contract renegotiations.
📋 Key Facts
- Effective date of amendment: June 7, 2024
- CEO Alan J. Tuchman's employment term extended to December 7, 2024
- Amendment includes automatic monthly renewal provisions thereafter
- The amendment is the third such modification to his original offer letter dated December 7, 2020
Synaptogenix, Inc. has implemented a one-time reverse stock split of its common stock at a ratio of 1-for-25. The transaction became effective after the close of trading on April 4, 2024.
🚩 Red Flags
- Reverse stock split (often used to combat delisting or improve share price perception).
- Ticker symbol change often accompanies significant restructuring or distress.
📋 Key Facts
- Reverse stock split ratio: 1-for-25.
- Effective Date/Time: April 4, 2024, at 5:00 p.m. ET (after market close).
- New Ticker Symbol: SNPX (previously TAOX).
- Fractional shares will be paid out in cash based on the closing price of April 4, 2024.
- Proportionate adjustments applied to stock options, warrants, and convertible securities.